Galanin modulates the activity of proopiomelanocortin neurons in the isolated mediobasal hypothalamus of the male rat.
It has become apparent that galanin as well as proopiomelanocortin-derived peptides, such as beta-endorphin, play an important role in the hypothalamic circuitry that regulates neuroendocrine functions and appetite behavior. We have recently shown that GalR1 and GalR2 galanin receptor mRNAs are expressed in proopiomelanocortin neurons of the arcuate nucleus, suggesting a direct modulatory action of galanin on the proopiomelanocortin neuronal system. In the present study, we investigated the effect of galanin on beta-endorphin release and proopiomelanocortin mRNA expression from male rat mediobasal hypothalamic fragments incubated ex vivo. Galanin induced a decrease of spontaneous beta-endorphin release within the first 30-60 min of incubation and this effect was blocked by the galanin receptor antagonist galantide. Co-incubation of galanin with FK-506 (tacrolimus), a calcineurin inhibitor, suppressed the inhibitory effect of galanin on beta-endorphin release, suggesting that calcineurin is involved in the galanin-evoked decrease in beta-endorphin release. Measurement of beta-endorphin levels in the tissues at the end of the incubation period (120 min) revealed that galanin caused a two-fold increase of beta-endorphin peptide concentration in the mediobasal hypothalamic tissues. Concurrently, galanin induced an increase in the mean density of silver grains overlying proopiomelanocortin neurons after 60 min of incubation, an effect antagonized by galantide. Finally, reverse transcription-polymerase chain reaction analysis revealed that the mRNAs for the three galanin receptor subtypes (i.e. GalR1, GalR2, and GalR3) were expressed in the incubated mediobasal hypothalamic fragments. Taken as a whole, our results indicate that galanin plays a modulatory role on proopiomelanocortin neurons and this interrelation contributes to the elucidation of the neural circuitry that controls, among others, gonadotropin-releasing hormone function.
Bouret
S
S
INSERM U-422, IFR 22, Neuroendocrinology and Neuronal Physiopathology, IFR 22, Place de Verdun, 59045 Lille, France. bouret@lille.inserm.fr
Croix
D
D
Mariot
M
M
Loyens
A
A
Prevot
V
V
Jegou
S
S
Vaudry
H
H
Beauvillain
J-C
JC
Mitchell
V
V
D000818:Animals; D065095:Calcineurin Inhibitors; D004305:Dose-Response Relationship, Drug; D019004:Galanin / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D007031:Hypothalamus / Q000737:chemistry / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D017403:In Situ Hybridization; D066298:In Vitro Techniques; D008297:Male; D009474:Neurons / Q000737:chemistry / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D011333:Pro-Opiomelanocortin / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis / Q000096:biosynthesis; D051381:Rats; D017208:Rats, Wistar; D044088:Receptors, Galanin; D018013:Receptors, Neuropeptide / Q000096:biosynthesis / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016559:Tacrolimus / Q000494:pharmacology; D001615:beta-Endorphin / Q000032:analysis / Q000378:metabolism
D065095:Calcineurin Inhibitors; D012333:RNA, Messenger; D044088:Receptors, Galanin; D018013:Receptors, Neuropeptide; D001615:beta-Endorphin; D011333:Pro-Opiomelanocortin; D019004:Galanin; D016559:Tacrolimus